doi:https://doi.org/

References:

Neal B., Perkovic V., de Zeeuw D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) — a randomized placebo-controlled trial. Am Heart J 2013;166(2):217—223.e11.
Neal B., Perkovic V., Matthews D.R., et al. Rationale, design and baseline char- acteristics of the CANagliflozin cardio- Vascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:387—393.
Neal B., Perkovic V., Mahaffey K.W., et al. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017;19:926—935..
Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117—2128.
Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323—334.
Cherney D.Z., Perkins B.A., Soleymanlou N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587—597.
Rabelink T.J., de Zeeuw D. The glycocalyx — linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol 2015;11:667—776.
Ballermann B.J., Brenner B.M. Atrial natriuretic peptide and the kidney. Am J Kidney Dis 1987;10:Suppl 1:7—12.
Emdin C.A., Rahimi K., Neal B., et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603—615.
Lv J., Ehteshami P., Sarnak M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013;185:949—957.
Ortola F.V., Ballermann B.J., Anderson S., et al. Elevated plasma atrial natriuretic peptide levels in diabetic rats: potential mediator of hyperfiltration. J Clin Invest 1987;80:670—674.
Perkovic V., Heerspink H.L., Chalmers J., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517—523.
Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405—412.
Vallianou N.G., Geladari E., Kazazis C.E. SGLT-2 inhibitors: their pleiotropic properties. Diabetes Metab Syndr 2016 December 9 (Epub ahead of print).
Wong M.G., Perkovic V., Chalmers J., et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016;39:694—700.
Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435—443.
Zoungas S., Arima H., Gerstein H.C., et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431—437.
Wu J.H., Foote C., Blomster J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411—419.
Verbeke G., Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
Watts N.B., Bilezikian J.P., Usiskin K., et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157—166.